Announcement on approval of reimbursement listing

Hirosaki LI announces that the reimbursement listing of the human (autologous) oral mucosa-derived epithelial cell sheet using human amniotic membrane substrate (brand name: Sakracy) as of September 1, 2022, has been approved in the general meeting of Central Social Insurance Medical Council held on August 3, 2022.